Eton Pharmaceuticals, Inc. has announced a significant milestone in its financial performance, reporting record third-quarter sales of $57.9 million for the period ending September 30, 2026. This figure represents a remarkable 158% increase compared to the same quarter last year. The company has not only achieved this growth but has also surpassed its annualized revenue run rate goal of $200 million five quarters ahead of schedule.

Sean Brynjelsen, CEO of Eton Pharmaceuticals, expressed enthusiasm about the results, stating, "Eton delivered another record quarter, with revenue of $57.9 million, up 158% year over year, and surpassed our $200 million annualized revenue run rate goal five quarters ahead of schedule. The team also demonstrated exceptional operational execution, significantly expanding margins, and delivering an adjusted EBITDA margin of 49%. We are raising both our revenue and adjusted EBITDA guidance for 2026, reflecting the strong momentum in our business."

Eton Pharmaceuticals, Inc., a Delaware-based company, operates in the pharmaceutical preparations industry (SIC 2834) and is listed on the Nasdaq under the ticker symbol ETON. The company focuses on developing and commercializing treatments for rare diseases, aiming to address unmet medical needs.

The recent SEC filing, dated November 5, 2026, reveals that Eton's financial results have been positively influenced by the strong performance of its product portfolio, which includes key products like HEMANGEOL, INCRELEX, and ALKINDI SPRINKLE. The company reported a fully diluted GAAP earnings per share (EPS) of $1.06 and a non-GAAP fully diluted EPS of $0.50 for the third quarter. Adjusted EBITDA for the quarter was $28.5 million, representing 49% of total revenue.

In addition to the impressive financial results, Eton Pharmaceuticals has raised its revenue guidance for 2026 to more than $175 million, up from a previous estimate of over $145 million. The company also increased its Adjusted EBITDA guidance to more than 40%, from a prior forecast of over 35%.

During the quarter, Eton achieved record levels of active patients across its key products. Brynjelsen noted, "Growth remained strong across the portfolio, with record levels of active patients for all of our key products." This growth is expected to continue as the company anticipates organic growth from its existing products throughout the remainder of 2026 and beyond.

Looking ahead, Eton Pharmaceuticals is also making strides in its pipeline development. The company has initiated the ET-900 program, which focuses on infantile and epileptic spasms. Furthermore, Eton has made significant advancements in its existing programs, including the FDA acceptance of the KHINDIVI label expansion submission and the completion of critical studies for its product formulations.

The filing does not specify what happens next, but the positive momentum in Eton's business suggests that the company will continue to pursue growth opportunities and enhance its product offerings.

As Eton Pharmaceuticals continues to achieve record sales and expand its market presence, it may set a benchmark for other companies in the pharmaceutical preparations industry to follow. The success of Eton's innovative approach to developing treatments for rare diseases could inspire competitors to enhance their own product lines and operational efficiencies.